FIELD: medicine. SUBSTANCE: method involves determining proliferative activity in the on-duty patches area and visually healthy skin in preclinical stage and out of season vague development course. Nuclear optic resonance value being equal to 1.21 and higher, fibrinogen concentration being 500.4 mg% on the background of fibrinolytic blood activity falling below 19.1%, psoriasis exacerbation is predicted. EFFECT: prevented recidivation on preclinical stage. 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING ATYPICAL FORM OF PSORIASIS | 2000 |
|
RU2200594C2 |
| METHOD FOR TREATING PSORIASIS | 1998 |
|
RU2152218C1 |
| METHOD OF STEPPED THERAPY OF PSORIASIS OF UNDEFINED CLINICAL COURSE | 2008 |
|
RU2398561C1 |
| METHOD FOR CARRYING OUT CYTOLOGICAL CONTROL OF PSORIASIS TREATMENT | 2000 |
|
RU2196331C2 |
| METHOD OF EXTERNAL TREATMENT OF LOCALISED PSORIASIS | 2007 |
|
RU2341301C2 |
| METHOD OF TREATING PATIENTS WITH PSORIASIS IN PROGRESSING STAGE | 2019 |
|
RU2716616C1 |
| METHOD OF TRANSDEMAL DRUG INTRODUCTION IN PSORIASIS TREATMENT WITH USING ELECTRET APPLICATORS | 2008 |
|
RU2386456C1 |
| METHOD OF TREATING PATIENTS WITH PSORIASIS IN PROGRESSING STAGE | 2019 |
|
RU2716617C1 |
| PSORIASIS TREATMENT METHOD | 1997 |
|
RU2142830C1 |
| METHOD FOR TREATMENT OF ALLERGIC DERMATOSIS | 2001 |
|
RU2230549C2 |
